Commentary on opinion pieces re Australian human papillomavirus vaccine policy.
The National Centre for Immunisation Research, The Children's Hospital at Westmead, Westmead, Australia. peterm@chw.edu.au
Peter
P
McIntyre
D000293:Adolescent; D000328:Adult; D001315:Australia; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D032541:Mass Vaccination / Q000191:economics; D030361:Papillomavirus Infections / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology; D019057:Quality-Adjusted Life Years; D015229:Sexually Transmitted Diseases, Viral / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000191:economics / Q000276:immunology / Q000517:prevention & control*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18